JP2014525901A5 - - Google Patents

Info

Publication number

JP2014525901A5

JP2014525901A5 JP2014517014A JP2014517014A JP2014525901A5 JP 2014525901 A5 JP2014525901 A5 JP 2014525901A5 JP 2014517014 A JP2014517014 A JP 2014517014A JP 2014517014 A JP2014517014 A JP 2014517014A JP 2014525901 A5 JP2014525901 A5 JP 2014525901A5

Authority

JP

Japan

Prior art keywords

amino acid

pharmaceutically acceptable

acceptable salt

peptide

seq

Prior art date

2012-06-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims 40
• 150000001413 amino acids Chemical group 0.000 claims 34
• 150000003839 salts Chemical class 0.000 claims 32
• 201000010099 disease Diseases 0.000 claims 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
• 102000051325 Glucagon Human genes 0.000 claims 5
• 108060003199 Glucagon Proteins 0.000 claims 5
• 210000004899 c-terminal region Anatomy 0.000 claims 5
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 5
• 229960004666 glucagon Drugs 0.000 claims 5
• 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 4
• 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 claims 4
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 125000000217 alkyl group Chemical group 0.000 claims 3
• 239000000539 dimer Substances 0.000 claims 3
• 125000006850 spacer group Chemical group 0.000 claims 3
• 108010063919 Glucagon Receptors Proteins 0.000 claims 2
• 102100040890 Glucagon receptor Human genes 0.000 claims 2
• 206010019708 Hepatic steatosis Diseases 0.000 claims 2
• 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 claims 2
• FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 2
• 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
• 208000008589 Obesity Diseases 0.000 claims 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
• 206010012601 diabetes mellitus Diseases 0.000 claims 2
• 230000000694 effects Effects 0.000 claims 2
• 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 2
• 235000020824 obesity Nutrition 0.000 claims 2
• 229920001223 polyethylene glycol Polymers 0.000 claims 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
• 108010016626 Dipeptides Proteins 0.000 claims 1
• IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 claims 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
• 108010002311 N-glycylglutamic acid Proteins 0.000 claims 1
• 239000002202 Polyethylene glycol Substances 0.000 claims 1
• 230000002378 acidificating effect Effects 0.000 claims 1
• 125000002252 acyl group Chemical group 0.000 claims 1
• 150000001408 amides Chemical group 0.000 claims 1
• 230000003178 anti-diabetic effect Effects 0.000 claims 1
• 239000000883 anti-obesity agent Substances 0.000 claims 1
• 239000003472 antidiabetic agent Substances 0.000 claims 1
• 229940125708 antidiabetic agent Drugs 0.000 claims 1
• 229940125710 antiobesity agent Drugs 0.000 claims 1
• 108091006116 chimeric peptides Proteins 0.000 claims 1
• 230000007850 degeneration Effects 0.000 claims 1
• 239000000032 diagnostic agent Substances 0.000 claims 1
• 229940039227 diagnostic agent Drugs 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000012634 fragment Substances 0.000 claims 1
• 230000004927 fusion Effects 0.000 claims 1
• YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000001537 neural effect Effects 0.000 claims 1
• 230000004770 neurodegeneration Effects 0.000 claims 1
• 102000039446 nucleic acids Human genes 0.000 claims 1
• 108020004707 nucleic acids Proteins 0.000 claims 1
• 150000007523 nucleic acids Chemical class 0.000 claims 1
• 229920000642 polymer Polymers 0.000 claims 1
• 229920001184 polypeptide Polymers 0.000 claims 1
• 102000004196 processed proteins & peptides Human genes 0.000 claims 1
• 239000002096 quantum dot Substances 0.000 claims 1
• 150000003384 small molecules Chemical class 0.000 claims 1
• 238000006467 substitution reaction Methods 0.000 claims 1
• 239000003053 toxin Substances 0.000 claims 1
• 231100000765 toxin Toxicity 0.000 claims 1